Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
1616 articles
October 202624
Primary Intermammary Breast Carcinoma Presenting With Direct Sternal Invasion: A Diagnostic Pitfall of Standard Screening Mammography.
An 85-year-old woman noticed a hard, non-tender sternal nodule despite an unremarkable screening mammogram 8 months earlier.
Peripheral Nerve Stimulation for Essential Tremor: a Systematic Review and Meta-Analysis of Effectiveness and Safety.
This systematic review and meta-analysis assessed peripheral nerve stimulation (PNS), including transcutaneous afferent patterned stimulation and transcutaneous peripheral nerve stimulation, for essential tremor.
Intracranial metastasis as a mimic of amyloid-related imaging abnormalities.
A 79-year-old woman with biomarker-confirmed Alzheimer’s disease developed progressive vasogenic edema while receiving lecanemab.
Epididymal cysts in children: a systematic review and meta-analysis of treatment approaches and clinical outcomes.
This PRISMA-compliant systematic review and meta-analysis synthesised observational evidence on epididymal cysts in boys younger than 18 years.
Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma.
This single-center, investigator-initiated phase II trial evaluated first-line nivolumab plus axitinib in patients with untreated unresectable or metastatic mucosal melanoma.
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.
This FDA approval summary describes evidence supporting erdafitinib for patients with FGFR3-altered locally advanced or metastatic urothelial carcinoma that progressed during or after at least one systemic therapy.
Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
This first-in-human, multicenter, open-label phase I/II study evaluated rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, in patients with PD-L1-positive advanced or metastatic non-small cell lung cancer…
FDA Approval Summary: Retifanlimab for the Treatment of Adult Patients with Metastatic or Inoperable Locally Recurrent Squamous Cell Carcinoma of the Anal Canal.
This FDA approval summary describes evidence from POD1UM-303, a randomised trial in 308 patients with advanced squamous cell carcinoma of the anal canal (SCAC) and no prior systemic treatment for advanced disease, and…
Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study.
This single-arm phase II study evaluated behavioral weight loss (BWL), with Contrave added for women with prior stage 0 to III breast cancer who lost less than 5% of their weight after two months.
Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics.
This single-centre, open-label phase I trial assessed intravenous autologous IL13Rα2-targeted CAR T cells in adults with recurrent, IL13Rα2-expressing grade 3–4 gliomas after standard treatment.
Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.
This randomized phase II trial biomarker analysis evaluated circulating thymidine kinase activity (TKa) in patients with BRAF V600-mutated metastatic melanoma receiving targeted therapy (TT), immune checkpoint…
Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial.
This multicenter, phase I trial evaluated multiantigen stimulated cell therapy I (MASCT-I), alone or with ifosfamide, as first-line maintenance therapy in 31 patients with advanced sarcoma whose disease was controlled…
Feasibility and Activity of Concurrent Neoadjuvant Chemotherapy and Radiotherapy in Patients with High-risk Soft-Tissue Sarcoma.
This analysis of the international, randomized phase III ISG-STS 1001 trial assessed concurrent epirubicin–ifosfamide chemotherapy (EI) and radiotherapy in patients with localized, high-risk soft-tissue sarcoma.
Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).
This multicenter phase I dose-escalation and dose-expansion study evaluated [177Lu]lutetium-dotatate plus oral triapine in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial.
This nonrandomized, multicenter, open-label, single-arm phase II trial evaluated first-line pembrolizumab plus necitumumab in 50 patients with previously untreated advanced NSCLC and PD-L1 tumor proportion score ≥50%.
A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.
BilT-02 was a multicenter phase II trial of rucaparib plus nivolumab as maintenance therapy for patients with advanced biliary tract cancer whose disease had not progressed after 4 to 6 months of first-line…
A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti-PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer.
This phase I dose-escalation and expansion study evaluated fractionated and repeated-cycle 225Ac-J591 in patients with progressive metastatic prostate cancer resistant to androgen pathway modulation.
AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
This prespecified biomarker analysis of the randomised ENZAMET trial assessed whether a locked artificial intelligence pathology image classifier (APIC) identified differential overall-survival benefit from enzalutamide…
Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial.
Brightline-1 was a randomized phase II/III trial comparing first-line brigimadlin with doxorubicin in patients with MDM2-amplified, locally advanced or metastatic dedifferentiated liposarcoma.
Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer.
This clinical-trial analysis examined whether multimodal tumour and clinical features could clarify exceptional responses to subtype-directed treatment in locally advanced HR+/HER2− breast cancer.
The impact of prophylactic azithromycin on the developing preterm gut microbiome and resistome.
This multicentre, double-blind, randomised, placebo-controlled trial examined the effects of 10 days of prophylactic intravenous azithromycin on the gut microbiome and resistome of 693 preterm infants born before 30…
Modulation of the gut microbiome and resistome by antibiotic use, but not by subsequent 2'-fucosyllactose intake, in adults with overweight or obesity.
This randomized, double-blind, placebo-controlled intervention examined gut microbiome and resistome changes in 18 adults with overweight or obesity after seven days of vancomycin, followed by eight weeks of…
Short-term Rhodiola rosea supplementation improves premenstrual symptoms, reaction time, and perceived exertion in female taekwondo athletes: a randomised double-blind placebo-controlled trial.
This randomised, double-blind, placebo-controlled trial tested 10 days of Rhodiola rosea (RR) supplementation during the estimated symptomatic premenstrual phase in 24 female taekwondo athletes with moderate-to-severe…
Psychoeducational interventions for children and adolescents with potentially traumatic experiences: a systematic review.
This systematic review examined stand-alone psychoeducational interventions for children and adolescents exposed to potentially traumatic experiences, including interventions delivered directly or through caregivers.
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.